Cancer despite immunosurveillance: immunoselection and immunosubversion

By L. Zitvogel, A. Tesnière, Guido Kroemer. Nature reviews. Immunology, 2006

1,349 citations recorded by the source corpus.

Subfields: Immunology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/cd0eb0c9bffbc43cbd6b6cf213e7bb5b62addb46

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. L. Galluzzi
3. D. Munn
4. L. Zitvogel
5. A. Mellor
6. D. Pardoll
7. Oliver Kepp
8. Lieping Chen

In Radiology, Nuclear Medicine and Imaging

1. Guido Kroemer
2. V. Bronte
3. M. Glennie

Citations in the corpus

• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (2010, background): “In support of cancer immunosurveillance is the fact that both immunodeficient or immunosuppressed patients and experimental animals are more susceptible to tumor development (for reviews see Dunn et al., 2004; Zitvogel et al., 2006; Swann and Smyth, 2007).”
• Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “In fact, successful escape from immune surveillance is considered one of the necessary hallmarks of cance”
• A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death (2012, neutral): “Interestingly, LPS and especially accidental necrotic cells stimulated the production of IL-10 (Figure 1D), whereas Hyp-PDT-treated cells failed to stimulate the production of this immunosuppressive cytokine (Kim et al , 2006; Zitvogel et al , 2006) by hu-iDCs.”
• Immunological aspects of cancer chemotherapy (2008, background): “Indeed, for the development of full-blown neoplasia , cancer cells have to overcome intrinsic (cell autonomous) and extrinsic (immune mediated) barriers to oncogenesi”
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial (2014, background): “Multiple resistance mechanisms, including systemic dysfunction in T-cell signaling(4-7) and exploitation of immune checkpoints,(8) evolve in tumors, helping them evade specific immune responses despite the presentation of tumor antigens to the immune system.(8) Recent understanding of these host-tum”
• Tumor cell metabolism: cancer's Achilles' heel. (2008, background): “Cancer cells differ from healthy cells due to a plethora of molecular changes (Hanahan and Weinberg, 2000; Zitvogel et al., 2006), many of which may be mechanistically linked to metabolic reprogramming (Figure 3).”
• Immunogenic cell death and DAMPs in cancer therapy (2012, background): “These authors showed that a recombinant N-terminal fragment of CRT (39-272) is a potent inducer of activation and maturation of B cells and macrophages and can trigger Ig class switching in B cells without T cell help in vitro and in vivo72.”
• Immune infiltration in human tumors: a prognostic factor that should not be ignored (2010, background): “Therefore, it is time to propose the immune reaction as a seventh hallmark of cancer, as proposed by Zitvogel et al. (2006), and to integrate the analysis and quantification of immune infiltrates as a routine prognostic factor.”
• Dynamics of the immune reaction to pancreatic cancer from inception to invasion. (2007, background): “lesions should trigger vigorous immune responses (1, 52), such as that observed in patientswith premalignantmonoclonal gammopathy (53).”
• The tumor microenvironment and its role in promoting tumor growth (2008, background): “Although these infiltrates of inflammatory cells can vary in size and composition from tumor to tumor, their presence has been taken as evidence that the host is not ignorant of the developing tumor, but rather attempts to interfere with tumor progression, a process referred to as immune surveillanc”
• NK cells and cancer immunosurveillance (2008, background): “Tumour cells employ many different strategies to evade immunosurveillance by NK cells (Zitvogel et al., 2006).”
• Immune parameters affecting the efficacy of chemotherapeutic regimens (2011, background): “Escape can result from active suppression of immune effectors, (immunosubversion), or from the loss of antigenic properties (immunoevasion)”